These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 33269395

  • 1. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
    Mills NT, Sampson E, Fourrier C, Baune BT.
    Int J Neuropsychopharmacol; 2021 Apr 21; 24(4):314-321. PubMed ID: 33269395
    [Abstract] [Full Text] [Related]

  • 2. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C, Sampson E, Mills NT, Baune BT.
    Trials; 2018 Aug 20; 19(1):447. PubMed ID: 30126458
    [Abstract] [Full Text] [Related]

  • 3. Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.
    Sampson E, Kavakbasi E, Mills NT, Hori H, Schubert KO, Fourrier C, Baune BT.
    Int J Neuropsychopharmacol; 2024 Mar 01; 27(3):. PubMed ID: 38441216
    [Abstract] [Full Text] [Related]

  • 4. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E, Sampson E, Mills NT, Hori H, Schwarte K, Hohoff C, Schubert KO, Clark SR, Fourrier C, Baune BT.
    J Neurochem; 2024 Sep 01; 168(9):1817-1825. PubMed ID: 37635396
    [Abstract] [Full Text] [Related]

  • 5. Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo.
    Sampson E, Mills NT, Hori H, Cearns M, Schwarte K, Hohoff C, Oliver Schubert K, Fourrier C, Baune BT.
    Brain Behav Immun; 2025 Jan 01; 123():43-56. PubMed ID: 39243988
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B.
    J Psychiatr Res; 2018 Jun 01; 101():72-79. PubMed ID: 29554497
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J, Liu XF, Feng C, Bao Q, Fu HR.
    Int J Psychiatry Clin Pract; 2019 Nov 01; 23(4):245-250. PubMed ID: 29113521
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M, Bose R, Schmidt SN.
    Curr Med Res Opin; 2024 Sep 01; 40(9):1637-1645. PubMed ID: 39110846
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 01; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 15. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F.
    Hum Psychopharmacol; 2018 Jan 01; 33(1):. PubMed ID: 29327372
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
    Di Nicola M, Adair M, Rieckmann A, Christensen M C.
    J Psychopharmacol; 2024 Jul 01; 38(7):615-623. PubMed ID: 39077889
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study.
    Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I.
    Int Clin Psychopharmacol; 2020 Nov 01; 35(6):305-312. PubMed ID: 32784346
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.